737 related articles for article (PubMed ID: 31623231)
1. The CD73/Ado System-A New Player in RT Induced Adverse Late Effects.
de Leve S; Wirsdörfer F; Jendrossek V
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623231
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.
de Leve S; Wirsdörfer F; Jendrossek V
Front Immunol; 2019; 10():698. PubMed ID: 31024543
[TBL] [Abstract][Full Text] [Related]
3. Host CD39 Deficiency Affects Radiation-Induced Tumor Growth Delay and Aggravates Radiation-Induced Normal Tissue Toxicity.
Meyer AV; Klein D; de Leve S; Szymonowicz K; Stuschke M; Robson SC; Jendrossek V; Wirsdörfer F
Front Oncol; 2020; 10():554883. PubMed ID: 33194619
[TBL] [Abstract][Full Text] [Related]
4. Adenosine can thwart antitumor immune responses elicited by radiotherapy : Therapeutic strategies alleviating protumor ADO activities.
Vaupel P; Multhoff G
Strahlenther Onkol; 2016 May; 192(5):279-87. PubMed ID: 26961686
[TBL] [Abstract][Full Text] [Related]
5. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
Bao X; Xie L
J Exp Clin Cancer Res; 2022 Jul; 41(1):222. PubMed ID: 35836249
[TBL] [Abstract][Full Text] [Related]
6. Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
Wirsdörfer F; de Leve S; Jendrossek V
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577587
[TBL] [Abstract][Full Text] [Related]
7. Modeling DNA damage-induced pneumopathy in mice: insight from danger signaling cascades.
Wirsdörfer F; Jendrossek V
Radiat Oncol; 2017 Aug; 12(1):142. PubMed ID: 28836991
[TBL] [Abstract][Full Text] [Related]
8. Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.
de Andrade Mello P; Coutinho-Silva R; Savio LEB
Front Immunol; 2017; 8():1526. PubMed ID: 29184552
[TBL] [Abstract][Full Text] [Related]
9. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape.
Montalbán Del Barrio I; Penski C; Schlahsa L; Stein RG; Diessner J; Wöckel A; Dietl J; Lutz MB; Mittelbronn M; Wischhusen J; Häusler SFM
J Immunother Cancer; 2016; 4():49. PubMed ID: 27532024
[TBL] [Abstract][Full Text] [Related]
10. Safety and potential increased risk of toxicity of radiotherapy combined immunotherapy strategy.
Guan H; Zhou Z; Hou X; Zhang F; Zhao J; Hu K
Asia Pac J Clin Oncol; 2023 Feb; 19(1):35-50. PubMed ID: 35538049
[TBL] [Abstract][Full Text] [Related]
11. ATP and Its Metabolite Adenosine as Regulators of Dendritic Cell Activity.
Silva-Vilches C; Ring S; Mahnke K
Front Immunol; 2018; 9():2581. PubMed ID: 30473700
[TBL] [Abstract][Full Text] [Related]
12. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
13. CD39/CD73/A2AR pathway and cancer immunotherapy.
Xia C; Yin S; To KKW; Fu L
Mol Cancer; 2023 Mar; 22(1):44. PubMed ID: 36859386
[TBL] [Abstract][Full Text] [Related]
14. Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors.
Chambers AM; Lupo KB; Wang J; Cao J; Utturkar S; Lanman N; Bernal-Crespo V; Jalal S; Pine SR; Torregrosa-Allen S; Elzey BD; Matosevic S
Elife; 2022 Jul; 11():. PubMed ID: 35815945
[TBL] [Abstract][Full Text] [Related]
15. Targeting the CD73-adenosine axis in immuno-oncology.
Allard D; Chrobak P; Allard B; Messaoudi N; Stagg J
Immunol Lett; 2019 Jan; 205():31-39. PubMed ID: 29758241
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
Reboul FL
Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
[TBL] [Abstract][Full Text] [Related]
17. CD73, Tumor Plasticity and Immune Evasion in Solid Cancers.
Yang H; Yao F; Davis PF; Tan ST; Hall SRR
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430239
[TBL] [Abstract][Full Text] [Related]
18. Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
Shi L; Yang L; Wu Z; Xu W; Song J; Guan W
Int Immunopharmacol; 2018 Oct; 63():58-65. PubMed ID: 30075429
[TBL] [Abstract][Full Text] [Related]
19. Enzyme activity of circulating CD73 in human serum.
Morello S; Turiello R; Madonna G; Pinto A; Ascierto PA; Capone M
Methods Enzymol; 2019; 629():257-267. PubMed ID: 31727244
[TBL] [Abstract][Full Text] [Related]
20. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
